drugset / Trial / NCT00903656
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Phase 2
Terminated
24 enrolled
Study Group of Medical Tumour Therapy (AGMT)
GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped: “Caelyx was not available anymore”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |